USPTO serial 86613156
NANOPARTICLE DRUG CONJUGATES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARK, JENNY K
- Law office
- TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NANOPARTICLE DRUG CONJUGATES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth A. Walker
ELIZABETH A. WALKER Choate Hall2 International Pl Ste 3200Boston, MA 02110-4120UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations and substances for diagnosis and targeted treatment of cancer and tumor diseases; pharmaceutical preparations and substances for diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; therapeutic agents for diagnosis and targeted treatment of cancer and tumor diseases; therapeutic agents for diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; therapeutic pharmaceuticals and substances for the diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for diagnosis and treatment of diseases and disorders; therapeutic agents for diagnosis and treatment of diseases and disorders | ACTIVE | — |
| 042 | research and development in the fields of pharmaceuticals, biotechnology, therapeutics, and drug formulation and delivery; research and development in the field of targeted therapies for cancer and tumor diseases; research and development in the field of targeted therapies for viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; consulting services in the field of scientific research; consulting services in the field of research and development for pharmaceuticals, biotechnology, therapeutics, and drug formulation and delivery; consulting services in the field of clinical trials; testing, inspection, research, or development of pharmaceutical and therapeutic preparations; pharmaceutical and therapeutic drug development services; pharmaceutical and therapeutic product evaluation; conducting early evaluations in the field of new pharmaceuticals and therapeutics; conducting quality control testing, feasibility testing, toxicology testing and pharmacology testing for pharmaceuticals and therapeutics; laboratory research services relating to pharmaceuticals and therapeutics; medical and scientific research, namely, conducting clinical trials for others; product safety testing for pharmaceuticals and therapeutics | INACTIVE - INSUFFICIENT FEE RECEIVED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 5, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 5, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 7, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 7, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 7, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 10, 2016 | ALIE | ASSIGNED TO LIE | — |
| Sep 2, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 11, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 6, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 9, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 1, 2015 | NWAP | NEW APPLICATION ENTERED | — |